In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases. China, where EC is the third most common female malignancy, accounted for nearly half of the new cases in Asia.
Novotech Awarded Cell & Gene Therapy CRO Excellence 2023
Singapore – 19 September 2023 - Novotech, the leading Asia Pacific centred biote
Read more